APA Zitierstil

Barr, P. M., Saylors, G. B., Spurgeon, S. E., Cheson, B. D., Greenwald, D. R., O’Brien, S. M., . . . Friedberg, J. W. (2016). Phase 2 study of idelalisib and entospletinib: Pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood.

Chicago Zitierstil

Barr, Paul M., et al. "Phase 2 Study of Idelalisib and Entospletinib: Pneumonitis Limits Combination Therapy in Relapsed Refractory CLL and NHL." Blood 2016.

MLA Zitierstil

Barr, Paul M., et al. "Phase 2 Study of Idelalisib and Entospletinib: Pneumonitis Limits Combination Therapy in Relapsed Refractory CLL and NHL." Blood 2016.

Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.